BCHT was founded都窗 in 2004, with the registered cap鐵城ital of RMB 130 million yuan風花. CCHT holds 46.15%微冷 of its shares and CCHT is the 醫睡largest shareholde他體r of ‘‘BCHT’’.

Dr. KONG Wei, the general manag友北er of BCHT, has been engaged in 民志the research of AIDS vaccin舞舊e and other bio拍錢logical vaccines at鐘離 Johns Hopkins U妹小niversity for a long tim樹商e. He is also an academ技問ic leader, an evaluation expert of 睡如the National Natural Science F歌對oundation of China, a “863 P學學lan” expert of Ministry of Science 友就and Technology of厭熱 the People’s Republic of China 哥會and an expert of Center for Drug Eval歌微uation, NMPA. He once gained the 站林national May 1 L月服abor Medal and the first ‘‘Outstanding錯不 Entrepreneurship Award’算請’ for Overseas Chinese Profession道些als granted by Overseas Chines店女e Affairs Office of the State Coun腦聽cil. He was also hono師從red as the winner of ‘‘special governm草生ent allowance of the State Council畫媽’’ and was selected into the nat頻道ional ‘‘New Century Talents Project’’.&章我nbsp;

‘‘BCHT’’ is Jilin Provincial 黃制Modern Vaccine Engineering Re文鄉search Center, Jilin Prov服鄉incial Vaccine Science a為西nd Technology In船舞novation Center a他白nd the Vaccine Engineering畫就 Research Center o議請f Changchun Nationa相去l Bioindustry Base. In 2008, its弟慢 leading product of varicella vac房城cine was launched, which has the l跳還ongest term of validity in the wor到資ld. This technol船銀ogy has reached the international樂用 advanced level and the curr匠空ent domestic market share 睡了is 35%. In 2020藍媽, its first exclusiv朋理e freeze-dried nasal spray liv區著e attenuated influenza vaccine (LA海窗IV) was launched in China, whic舊頻h was also a cooperati微靜ve project of WHO influenza視人 action plan.